The fractionated dosage of GO was observed in the phase 2 MyloFrance‐1 trial for the first Relapsed or refractory (R/R) CD33‐positive AML patients; 26% of patients achieved complete remission (CR) with a median relapse‐free survival (RFS) of 11 months and manageable toxicities, which led to FDA approval.54 The gene discussed is CD33; the disease is acute myeloid leukemia.